Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - What's Next?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $10.21, but opened at $9.98. Capricor Therapeutics shares last traded at $11.06, with a volume of 875,832 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CAPR shares. Roth Capital assumed coverage on Capricor Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $31.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.50.

Capricor Therapeutics Stock Performance

The stock has a 50 day moving average of $10.15 and a two-hundred day moving average of $13.03. The stock has a market cap of $588.32 million, a PE ratio of -12.15 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. During the same period last year, the business earned ($0.31) EPS. Analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Several institutional investors have recently made changes to their positions in the business. Summit Investment Advisors Inc. raised its stake in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares during the period. Virtus ETF Advisers LLC acquired a new stake in Capricor Therapeutics in the fourth quarter worth about $68,000. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $78,000. Finally, New York State Common Retirement Fund grew its holdings in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after buying an additional 5,000 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.